Compare DELL & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DELL | AZN |
|---|---|---|
| Founded | 1984 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.9B | 250.7B |
| IPO Year | 2013 | 1995 |
| Metric | DELL | AZN |
|---|---|---|
| Price | $540.52 | $157.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 11 |
| Target Price | ★ $579.36 | $212.17 |
| AVG Volume (30 Days) | ★ 8.6M | 2.6M |
| Earning Date | 09-01-2026 | 10-30-2026 |
| Dividend Yield | 0.47% | ★ 2.00% |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 11.58 | N/A |
| Revenue | ★ $113,538,000,000.00 | N/A |
| Revenue This Year | $70.44 | $7.54 |
| Revenue Next Year | $15.76 | $6.09 |
| P/E Ratio | $47.37 | ★ $31.91 |
| Revenue Growth | ★ 18.80 | N/A |
| 52 Week Low | $110.22 | $80.48 |
| 52 Week High | $595.51 | $212.71 |
| Indicator | DELL | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 43.70 |
| Support Level | $530.45 | $154.89 |
| Resistance Level | $595.51 | $169.77 |
| Average True Range (ATR) | 22.54 | 2.62 |
| MACD | -5.74 | -0.20 |
| Stochastic Oscillator | 17.41 | 6.49 |
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners and also relies heavily on channel partners to fulfill its sales.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.